These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22344275)

  • 21. MHC presentation via autophagy and how viruses escape from it.
    Gannage M; Münz C
    Semin Immunopathol; 2010 Dec; 32(4):373-81. PubMed ID: 20857294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding domain regulation of MHC class II molecule assembly, trafficking, fate, and function.
    Germain RN
    Semin Immunol; 1995 Dec; 7(6):361-72. PubMed ID: 8775462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Business as usual: the p35 isoform of human CD74 retains function in antigen presentation.
    Bergmann H
    Immunol Cell Biol; 2012 Oct; 90(9):839-40. PubMed ID: 23032370
    [No Abstract]   [Full Text] [Related]  

  • 24. Biologic consequences of defective major histocompatibility complex class II presentation.
    Eibl MM; Wolf HM
    Curr Top Microbiol Immunol; 1998; 232():217-40. PubMed ID: 9557400
    [No Abstract]   [Full Text] [Related]  

  • 25. Inducing efficient cross-priming using antigen-coated yeast particles.
    Howland SW; Tsuji T; Gnjatic S; Ritter G; Old LJ; Wittrup KD
    J Immunother; 2008 Sep; 31(7):607-19. PubMed ID: 18600183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autophagy and MHC-restricted antigen presentation.
    Valečka J; Almeida CR; Su B; Pierre P; Gatti E
    Mol Immunol; 2018 Jul; 99():163-170. PubMed ID: 29787980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular transport of molecules engaged in the presentation of exogenous antigens.
    Nordeng TW; Gorvel JP; Bakke O
    Curr Top Microbiol Immunol; 1998; 232():179-215. PubMed ID: 9557399
    [No Abstract]   [Full Text] [Related]  

  • 29. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.
    Frauwirth K; Shastri N
    Immunology; 2001 Apr; 102(4):405-15. PubMed ID: 11328374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of autophagy in MHC class I-restricted antigen presentation.
    Van Kaer L; Parekh VV; Postoak JL; Wu L
    Mol Immunol; 2019 Sep; 113():2-5. PubMed ID: 29126597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential use of autophagy by primary dendritic cells specialized in cross-presentation.
    Mintern JD; Macri C; Chin WJ; Panozza SE; Segura E; Patterson NL; Zeller P; Bourges D; Bedoui S; McMillan PJ; Idris A; Nowell CJ; Brown A; Radford KJ; Johnston AP; Villadangos JA
    Autophagy; 2015; 11(6):906-17. PubMed ID: 25950899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accessory molecules for MHC class II peptide loading.
    Busch R; Doebele RC; Patil NS; Pashine A; Mellins ED
    Curr Opin Immunol; 2000 Feb; 12(1):99-106. PubMed ID: 10679402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus.
    Badve S; Deshpande C; Hua Z; Lögdberg L
    J Histochem Cytochem; 2002 Apr; 50(4):473-82. PubMed ID: 11897800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.
    Moffat JM; Cheong WS; Villadangos JA; Mintern JD; Netter HJ
    Vaccine; 2013 Apr; 31(18):2310-6. PubMed ID: 23473776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
    Albert LJ; Ghumman B; Watts TH
    J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.
    Lizée G; Basha G; Tiong J; Julien JP; Tian M; Biron KE; Jefferies WA
    Nat Immunol; 2003 Nov; 4(11):1065-73. PubMed ID: 14566337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unique approach for B lymphoma therapy.
    Epstein AL
    Blood; 2012 Apr; 119(16):3647-8. PubMed ID: 22517869
    [No Abstract]   [Full Text] [Related]  

  • 39. [MHC class II restricted antigen presentation].
    Hirata S; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():299-303. PubMed ID: 15861672
    [No Abstract]   [Full Text] [Related]  

  • 40. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
    Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
    Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.